Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Prepares To Launch LAI Risperidone After US Approval

MedinCell-Partnered Schizophrenia Treatment Uzedy Has Now Been Approved By US FDA

Executive Summary

Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.

You may also be interested in...

Teva Looks To Novartis To Replace Departing Dethlefs

Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.

Viatris Welcomes FDA Date On Slow-Release Copaxone Product

Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once- monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis.

Teva Outlines US Opportunities Amid North American Decline

With Teva continuing to report declining North American generics sales – albeit more than offset by increases in other territories and business units – the company has highlighted future targets in the US as it pushes forward with its new “pivot to growth” strategy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts